z-logo
open-access-imgOpen Access
Enhanced antibacterial effect against Enterococcus faecalis by silver ions plus Triton X-100 with low concentrations and cytotoxicity
Author(s) -
Mengting Duan,
Qing Sun,
Wei Fan,
Bing Fan
Publication year - 2021
Publication title -
brazilian journal of microbiology
Language(s) - English
Resource type - Journals
eISSN - 1678-4405
pISSN - 1517-8382
DOI - 10.1007/s42770-021-00643-8
Subject(s) - enterococcus faecalis , cytotoxicity , biofilm , chlorhexidine , antibacterial activity , microbiology and biotechnology , root canal , chemistry , antibiotics , minimum inhibitory concentration , nuclear chemistry , bacteria , in vitro , biology , medicine , dentistry , biochemistry , escherichia coli , genetics , gene
Enterococcus faecalis (E. faecalis) is commonly considered to be one of chief culprits of secondary and persistent root canal infections. As antibiotic resistance has become a global issue, in order to reduce the use of antibiotics, metal ions have recently been widely used as an alternative. Silver ions (Ag + ) have been proved to be a strong bactericide but with high cytotoxicity and discoloration property. Triton X-100 (TX-100) and Ag + were co-used for the first time as a clinical intracanal medication to obtain both enhanced antibacterial effect and low cytotoxicity. The synergistic antibacterial effect of TX-100 + Ag + was tested on both planktonic and biofilm-resident E. faecalis on dentine. And the cytotoxicity was tested on MC3T3-E1 cells. Results confirmed the antibacterial activity against both planktonic and biofilm-resident E. faecalis was dramatically improved after TX-100 incorporation. TX-100 and Ag + mixture demonstrated a similar inhibitory effect as the 2% chlorhexidine (CHX), while the cytotoxicity was much lower than 2% CHX (p < 0.05). In conclusion, TX-100 + Ag + mixture might be developed into a new effective intracanal medication as the 2% CHX.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here